V Vicennati
Overview
Explore the profile of V Vicennati including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
887
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nannini M, Repaci A, Nigro M, Colapinto A, Vicennati V, Maloberti T, et al.
ESMO Open
. 2024 Dec;
9(11):103704.
PMID: 39617534
No abstract available.
2.
Palandri F, Branzanti F, Venturi M, Dedola A, Fontana G, Loffredo M, et al.
Ann Hematol
. 2024 May;
103(7):2347-2354.
PMID: 38771499
Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no symptomatic splenomegaly. There is currently lack of information on the...
3.
Nannini M, Repaci A, Nigro M, Colapinto A, Vicennati V, Maloberti T, et al.
ESMO Open
. 2023 Oct;
8(6):102039.
PMID: 37879236
Background: Tumor genotyping is becoming crucial to optimize the clinical management of patients with advanced differentiated thyroid cancer (DTC); however, its implementation in clinical practice remains undefined. We herein report...
4.
Gambineri A, Scarano E, Rucci P, Perri A, Tamburrino F, Altieri P, et al.
J Endocrinol Invest
. 2022 Jul;
45(12):2247-2256.
PMID: 35907176
Purpose: Many questions concerning Turner syndrome (TS) remain unresolved, such as the long-term complications and, therefore, the optimal care setting for adults. The primary aim of this long-term cohort study...
5.
De Leo A, Vara G, Paccapelo A, Balacchi C, Vicennati V, Tucci L, et al.
J Endocrinol Invest
. 2022 Jun;
45(10):1935-1944.
PMID: 35680695
Objectives: Pheochromocytomas are rare tumors which can present with heterogeneous secretion profiles, clinical manifestations, and radiologic appearance. Under a histopathological point of view, they can be characterized as more or...
6.
Oriolo C, Fanelli F, Castelli S, Mezzullo M, Altieri P, Corzani F, et al.
J Endocrinol Invest
. 2020 Apr;
43(10):1499-1509.
PMID: 32236851
Objective: We aimed at defining the most effective routine immunoassay- or liquid chromatography-tandem mass spectrometry (LC-MS/MS)-determined steroid biomarkers for identifying non-classic adrenal hyperplasia due to 21-hydroxylase deficiency (21-NCAH) in a...
7.
De Leo A, Mosconi C, Zavatta G, Tucci L, Nanni C, Selva S, et al.
J Endocrinol Invest
. 2020 Feb;
43(9):1197-1204.
PMID: 32062826
Background: Adrenal lipid-poor adenomas (LPA) are defined by high unenhanced density (≥ 10 HU), and absolute and relative contrast medium washout > 60% and > 40%, respectively, at computerized tomography...
8.
Bazzocchi A, Diano D, Vicennati V, Pizzi C, De Filippo M, Pasquali R, et al.
Clin Obes
. 2015 Jan;
3(5):132-40.
PMID: 25586628
What Is Already Known About This Subject: Obesity is an increasingly prevalent metabolic disorder and it is associated with a large number of comorbidities, including cardiovascular diseases. Adipose tissue is...
9.
Pasquali R, Vicennati V, Gambineri A, Pagotto U
Int J Obes (Lond)
. 2008 Oct;
32(12):1764-79.
PMID: 18838976
Obesity, particularly its abdominal phenotype, a harbinger of the metabolic syndrome, cardiovascular diseases (CVDs) and type 2 diabetes mellitus (T2D), is becoming one of the most significant public health problems...
10.
Bellocchio L, Cervino C, Vicennati V, Pasquali R, Pagotto U
J Neuroendocrinol
. 2008 May;
20 Suppl 1:130-8.
PMID: 18426512
The endocannabinoid system has recently emerged as an important modulator of several functions of adipose tissue, including cell proliferation, differentiation and secretion. Here, we will review the effects of cannabinoid...